# EDGAR Filing Document

**Accession Number:** 0001988760
**File Stem:** 0001999371-25-007493
**Filing Date:** 2025-6
**Character Count:** 20956
**Document Hash:** 4c6a8bcd35214e15222a3d89a22c7cb1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-25-007493.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001999371-25-007493

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UroGen Pharma Ltd.
- **CENTRAL INDEX KEY:** 0001668243
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89992
- **FILM NUMBER:** 251035555

**BUSINESS ADDRESS:**
- **STREET 1:** 9 HA'TA'ASIYA ST
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4365007
- **BUSINESS PHONE:** 972 9 770 7601

**MAIL ADDRESS:**
- **STREET 1:** 9 HA'TA'ASIYA ST
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4365007
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Monograph Capital Holdings Advisors, LLC
- **CENTRAL INDEX KEY:** 0001988760

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 4001 KENNETT PIKE
- **STREET 2:** SUITE 302
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19807
- **BUSINESS PHONE:** (208) 720-9157

**MAIL ADDRESS:**
- **STREET 1:** 4001 KENNETT PIKE
- **STREET 2:** SUITE 302
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19807

## Exhibit 99.1

**Schedule 1**

This Schedule sets forth information with respect to each sale of Ordinary Shares which were effectuated on the Nasdaq by the Reporting Person during the sixty (60) days prior to the date of event which required the filing of this statement through the date of the filing of this statement. The prices below reflect the price paid by the purchasers per Ordinary Share on the relevant trade date.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reporting**<br> **Person** | **Type of**<br> **Transaction** | **Trade**<br> **Date** | **Number of**<br> **Shares** | **Price per**<br> **Share** |
| Monograph Capital Partners I, L.P. | Sold | 5/27/2025 | 74473 | $3.97 (1) |
| Monograph Capital Partners I, L.P. | Sold | 5/28/2025 | 134149 | $4.01 (2) |
| Monograph Capital Partners I, L.P. | Sold | 5/29/2025 | 38537 | $3.97 (3) |
| Monograph Capital Partners I, L.P. | Sold | 5/30/2025 | 145922 | $3.89 (4) |
| Monograph Capital Partners I, L.P. | Sold | 6/05/2025 | 111303 | $5.10 (5) |
| Monograph Capital Partners I, L.P. | Sold | 6/06/2025 | 85237 | $5.71 (6) |
| Monograph Capital Partners I, L.P. | Sold | 6/06/2025 | 144091 | $6.01 (7) |

---

------

1. Weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.2228 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote 1.

2. Weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.06 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote 2.

3. Weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.11 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote 3.

4. Weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.235 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote 4.

5. Weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.15 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote 5.

6. Weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.05 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote 6.

7. Weighted average price. These shares were sold in multiple transactions at prices ranging from $5.57 to $6.28 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote 7.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**UroGen Pharma Ltd.**

*(Name of Issuer)*

**Ordinary Shares, par value NIS 0.01 per share**

*(Title of Class of Securities)*

**M96088105**

*(CUSIP Number)*

**Michael LaGatta, Partner & COO**<br>Monograph Capital Partners I, L.P.<br>4001 Kennett Pike Suite 302<br>Wilmington DE 19807<br>(208) 720-9157

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/05/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **M96088105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Monograph Capital Partners I, L.P.** | Name of reporting person<br>**Monograph Capital Partners I, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**838615.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**838615.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.8%** | Percent of class represented by amount in Row (11)<br>**1.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percent calculation based on 46,107,451 shares of Ordinary Shares (as defined in Item 1 below) issued and outstanding as of May 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on May 12, 2025 (the "Form 10-Q").

| **CUSIP No.** | **M96088105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Monograph Capital Partners I GenPar, LP** | Name of reporting person<br>**Monograph Capital Partners I GenPar, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**838615.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**838615.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.8%** | Percent of class represented by amount in Row (11)<br>**1.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percent calculation based on 46,107,451 shares of Ordinary Shares issued and outstanding as of May 5, 2025, as reported in the Form 10-Q.

| **CUSIP No.** | **M96088105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Monograph Capital Holdings Advisors, LLC** | Name of reporting person<br>**Monograph Capital Holdings Advisors, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**838615.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**838615.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.8%** | Percent of class represented by amount in Row (11)<br>**1.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Percent calculation based on 46,107,451 shares of Ordinary Shares issued and outstanding as of May 5, 2025, as reported in the Form 10-Q.

| **CUSIP No.** | **M96088105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fred Cohen** | Name of reporting person<br>**Fred Cohen** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**15000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**838615.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**15000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**838615.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.9%** | Percent of class represented by amount in Row (11)<br>**1.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Percent calculation based on 46,107,451 shares of Ordinary Shares issued and outstanding as of May 5, 2025, as reported in the Form 10-Q.

| **CUSIP No.** | **M96088105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Charles Conn** | Name of reporting person<br>**Charles Conn** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**838615.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**838615.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | Aggregate amount beneficially owned by each reporting person<br>**838615.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.8%** | Percent of class represented by amount in Row (11)<br>**1.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Percent calculation based on 46,107,451 shares of Ordinary Shares issued and outstanding as of May 5, 2025, as reported in the Form 10-Q.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, par value NIS 0.01 per share

**(b) Name of Issuer:**
UroGen Pharma Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
400 Alexander Park Drive, Princeton, NJ, 08540

This Amendment No. 1 (the "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons on August 4, 2023 (the "Original Schedule 13D" and, as amended and supplemented by this Amendment, the "Schedule 13D"), with respect to the Ordinary Shares, par value NIS 0.01 per share (the "Ordinary Shares"), of UroGen Pharma Ltd., a company organized under the laws of the State of Israel (the "Issuer"). The filing of this Amendment represents the final amendment to the Schedule 13D and constitutes an "exit filing" for the Reporting Person.

Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Original Schedule 13D. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to them in the Original Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date hereof, Monograph I owns directly (and therefore is deemed the beneficial owner of) 838,615 Ordinary Shares, which represents approximately 1.8% of the number of Ordinary Shares outstanding.

**(b)**
Each of GenPar I, GovCo, Mr, Cohen and Mr. Conn may be deemed to share voting and investment power over the shares of Ordinary Shares owned by Monograph I because (i) Messrs. Cohen and Conn are managing members of GovCo, (ii) GovCo is the general partner of GenPar I and (iii) GenPar I is the general partner of Monograph I.

Mr. Cohen owns directly and has sole voting and investment power over 15,000 Ordinary Shares.

**(c)**
From May 27 to June 6, 2025, the Reporting Persons sold a total of 733,712 Ordinary Shares, amounting to 1.6% of Ordinary Shares outstanding. As of such latter date, the Reporting Persons no longer beneficially own more than 5% of Ordinary Shares outstanding and accordingly are no longer subject to beneficial ownership reporting requirements with respect to the shares under Section 13 of the Securities Exchange Act of 1934, as amended.

All transactions in Ordinary Shares effected by the Reporting Persons during the past sixty days are listed in Schedule 1 hereto and incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Monograph Capital Partners I, L.P.

**Signature:** /s/ Michael LaGatta

**Name/Title:** Michael LaGatta / Partner and Authorized Signatory

**Date:** 06/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Monograph Capital Partners I GenPar, LP

**Signature:** /s/ Michael LaGatta

**Name/Title:** Michael LaGatta / Partner and Authorized Signatory

**Date:** 06/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Monograph Capital Holdings Advisors, LLC

**Signature:** /s/ Michael LaGatta

**Name/Title:** Michael LaGatta / Partner and Authorized Signatory

**Date:** 06/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fred Cohen

**Signature:** /s/ Michael LaGatta

**Name/Title:** Michael LaGatta/ Attorney-in-fact (1)

**Date:** 06/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Charles Conn

**Signature:** /s/ Michael LaGatta

**Name/Title:** Michael LaGatta/ Attorney-in-fact (2)

**Date:** 06/09/2025